PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
(USA) Initial information was received on 21Aug2014 from the prescriber regarding the 71 year old male who 
received Pomalyst for the treatment of multiple myeloma diagnosed in 2007. According to information previously 
provided, the patient was dispensed Pomalyst 4mg orally daily from Jul 2013. The patient was previously treated 
with multiple cycles of Revlimid and dexamethasone followed by an autologous transplant. The patient was started 
on Pomalyst  for his relapsed disease in conjunction with dexamethasone. The lot number and expiration date was 
not provided. On an unknown date, the patient developed abrupt onset of cognitive issues. The prescriber just saw 
the patient in clinic in mid July and he was doing well. 
On (b) (6)  the patient was hospitalized due to a final diagnosis of life threatening progressivemultifocal 
leukoencephalopathy. The etiology of the event or laboratory/diagnostic results were not provided. The outcome of 
the event was not recovered. Pomalyst was permanently discontinued this month due to the event. The patient was 
sent to hospice care
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 258 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
The reporter did not provide an assessment of the causal relationship of the event with Pomalyst. 
Additional  information will be requested.